Pipan Oils Share Price
185.15+0.00 (+0.00%)
+2.98% past 1 Year
Financial overview
Peer Comparison
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Balance Sheet
Consolidated
Standalone
₹
%
Cash Flow
Consolidated
Standalone
₹
%
Fundamental Ratios
Consolidated
Standalone
Pipan Oils Share Price
185.15+0.00 (+0.00%)
+2.98% past 1 Year
Technical meters

No results found
Pivot
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Pipan Oils Share Price
185.15+0.00 (+0.00%)
+2.98% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly

No results found
Bulk & block deals

No results found
Insider trading & SAST

No results found
Pipan Oils Share Price
185.15+0.00 (+0.00%)
+2.98% past 1 Year
Corporate Actions
Date
Type
Details
Company details
Pipan Oils Share Price
185.15+0.00 (+0.00%)
+2.98% past 1 Year
Corporate filings & documents

No corporate filings & documents found
Pipan Oils Share Price
185.15+0.00 (+0.00%)
+2.98% past 1 Year
News
Allied Blenders Co Promoter Plans Sale Of 55 Lakh Shares
Equity
ABDL
Pearl Global expands Bangladesh manufacturing capacity to 10.80 crore pieces annually
Equity
PGIL
Power Grid Board To Consider Raising Funds Through Rupee Term Loan
Equity
POWERGRID
Borosil Reassesses Gujarat Plant Plans With Rs 42 Crores Investment
Equity
BOROLTD
Iran Signals Strait Of Hormuz Reopening If US Eases Military Pressure
Broader Market
RITES Secures Contract Valued At Rs 155 Crores
Equity
RITES
Tempsens Instruments expects new capacity utilization by fiscal year 2030
Equity
TEMPSENS
Tempsens Instruments Announces Four New Projects With Rs 500 Crores Revenue Potential
Equity
TEMPSENS
Tempsens Instruments Expects Profit Growth To Match Revenue Growth By Fiscal Year 2027
Equity
TEMPSENS
Tempsens Instruments Expects Sustained Revenue Growth With Stable Margins Ahead
Equity
TEMPSENS
Tempsens clarifies outlook and capacity revenue potential is indicative
Equity
TEMPSENS
Symbiotec Pharmalab Signs Term Sheet With Large US Pharma Company
Equity
SYMBIOTEC
Symbiotec Pharmalab maintains API gross margin guidance near 60 percent
Equity
SYMBIOTEC
Symbiotec Pharmalab Plans Annual Capex Investment Of Rs 200 Crores To Rs 250 Crores
Equity
SYMBIOTEC
Symbiotec Pharmalab expects milestone cash flows in second half of FY27
Equity
SYMBIOTEC
Symbiotec Pharmalab expects elevated new business expenses to pressure profitability
Equity
SYMBIOTEC
Symbiotec Pharmalab Targets Revenue And EBITDA Growth In Current Fiscal Year
Equity
India US Trade Talks Continue In Positive Direction Says Trade Minister Goyal
Broader Market
Hikal Begins Panoli Production For Global Personal Care Ingredients
Equity
HIKAL
Borosil Scientific Approves Bharuch Glassware Facility Expansion To Raise Annual Production
Equity
BOROSCI

